Clinical

Dataset Information

0

Fruquintinib in the Cross-line Treatment of Refractory mCRC


ABSTRACT: This is a real-world study. Patients with metastatic colorectal cancer who have progressed (PD) after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as fourth-line therapy. The objective of this study was to observe the efficacy and safety of cross-line(from third to fourth line)treatment with fruquinitinib.

DISEASE(S): Fruquintinib,Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 114606 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 9849 | ecrin-mdr-crc
| 2740163 | ecrin-mdr-crc
| 65224 | ecrin-mdr-crc
| 91504 | ecrin-mdr-crc
| 2380401 | ecrin-mdr-crc
| 2386605 | ecrin-mdr-crc
| 2354180 | ecrin-mdr-crc
| 1194 | ecrin-mdr-crc
| 58835 | ecrin-mdr-crc
| 2759471 | ecrin-mdr-crc